Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 5/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | PYGL | P06737 | 2/20 | 0.42 |
| ▸ | PYGM | P11217 | 2/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13860977 | 0.92 | AXL (0.52) | AXLMETALDH1A1MAPTLMNA | |
| SCHEMBL13860834 | 0.92 | KDR (0.47) | AXLMETGCKKDRBRAF | |
| SCHEMBL4335165 | 0.92 | AXL (0.45) | AXLMETALDH1A1GCKKMT2A | |
| SCHEMBL4333626 | 0.91 | KDR (0.48) | AXLMETGCKKDRBRAF | |
| SCHEMBL13861293 | 0.90 | AXL (0.43) | AXLMETGCKKDRBRAF | |
| SCHEMBL13861568 | 0.90 | AXL (0.45) | AXLMETALDH1A1LMNAGCK | |
| SCHEMBL4342802 | 0.88 | ALDH1A1 (0.46) | AXLMETALDH1A1GCKKDR | |
| SCHEMBL13861353 | 0.88 | MAPT (0.46) | AXLMETALDH1A1MAPTGCK | |
| SCHEMBL13860835 | 0.88 | GAA (0.46) | AXLMETGAAALDH1A1MAPT | |
| SCHEMBL13861566 | 0.88 | AXL (0.51) | AXLMETMAPTLMNAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881976-B1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1881976-B1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-1719762-B1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | EISAI R&D MAN CO LTD (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | KIM TAE-SEONG (US) | 2012-03-22 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088794-B2 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
| EP-1881976-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Amgen Inc., (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| EP-1719763-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (2) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-1719762-A1 | NOVEL PYRIDINE DERIVATIVE AND PYRIMIDINE DERIVATIVE (1) | Eisai Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006116713-A1 | SUBSTITUTED AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | EISAI CO., LTD. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | AXL 87/4885MET 2/4885GAA 4724/4885 |
| US-20050277652-A1 | Novel pyridine derivative and pyrimidine derivative | HGF, MET, HDGF | AXL 116/4885MET 2/4885GAA 4724/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | AXL 475/4885MET 545/4885GAA 803/4885 |
| US-20120070413-A1 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES | HGF, HGFAC, MET | AXL 855/4885MET 3/4885GAA 78/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | AXL 776/4885MET 3/4885GAA 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.